January 9, 2013

The size and number of recent settlements for regulatory compliance failures raise a key question for board members: how should the board’s fiduciary responsibility translate into concrete action? NAI Consultant Stephen Rothenberg, J.D., addresses this topic in his article, The Board’s Role in Pharmaceutical Compliance. Stephen also offers a structured approach to evaluating progress toward best-in-class compliance based on board actions and outcomes, called the Compliance Program Maturity Level.

See the full article, published in Pharmaceutical Compliance Monitor, January 2013, here.